Research Fellow / Senior Research Fellow

This role will involve working across the myeloma and immunotherapy labs in UCL to drive the above project, You will develop new approaches to CAR-T design based on rational modulation of T cell function, and evaluate CAR-T cell activity primarily in vivo. Using skills of protein engineering, CRISPR screening in combination with detailed phenotyping by high dimensional flow cytometry, single cell and bulk sequencing, and TCR sequencing. You will be highly experienced in flow cytometry, including the design of high dimensional panels, molecular biology, and have an understanding of cancer immunology. You will be required to set up new platforms as required for the successful execution of the project.

The successful candidate must have a PhD in a related subject and laboratory experience. Immunology or Cancer biology background favoured. A BSc (2:1) in biomedical sciences or a related subject is essential. Experience in CRISPR screening platforms and previous exposure to tumour immunology are desirable but not essential. For appointment at Grade 8 successful candidates must demonstrate evidence of independent working and leadership and management experience and ability. Ability to present work and represent PI independently will be essential.

The UCL Cancer Institute (https://www.ucl.ac.uk/cancer/) is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 400 talented scientists who are working together to translate research discoveries into developing kinder, more effective therapies for cancer patients. The Cancer Institute includes the Cancer Research UK and UCL Cancer Trials Centre which is one of the largest cancer trials centres in the UK conducting multi-centre national and international phase III trials, feasibility studies and early phase I and II studies. Multiple myeloma is a common but largely incurable blood cancer. Despite therapeutic advances, there remains an unmet need for new treatments. Chimeric antigen receptors or CARs have been a medical breakthrough of a generation and show promise in myeloma. UCL has the largest CAR T cell program in Europe and the largest myeloma practice nationally. We developed the first myeloma CAR to enter clinical trials in Europe and, have the only recruiting academic CAR T cell trial in the UK for this condition., You can read more about our commitment to Equality, Diversity and Inclusion here : https://www.ucl.ac.uk/equality-diversity-inclusion

Salary offered for this post will either be on grade 7: £42,099 - £50,585 per annum or grade 8: £51,474 - £60,521 per annum inclusive of London Allowance. Appointment at Grade 7 is dependent upon having been awarded a PhD; if this is not the case, initial appointment will be at research assistant Grade 6B with payment at Grade 7 being backdated to the date of final submission of the PhD thesis., As well as the exciting opportunities this role presents we also offer some great benefits some of which are below:

• 41 Days holiday (including 27 days annual leave 8 bank holiday and 6 closure days)
• Defined benefit career average revalued earnings pension scheme (CARE)
• Cycle to work scheme and season ticket loan
• On-Site nursery
• On-site gym
• Enhanced maternity, paternity and adoption pay
• Employee assistance programme: Staff Support Service
• Discounted medical insurance
Our commitment to Equality, Diversity and Inclusion As London's Global University, we know diversity fosters creativity and innovation, and we want our community to represent the diversity of the world's talent. We are committed to equality of opportunity, to being fair and inclusive, and to being a place where we all belong. We therefore particularly encourage applications from candidates who are likely to be underrepresented in UCL's workforce. These include people from Black, Asian and ethnic minority backgrounds; disabled people; LGBTQI+ people; and for our Grade 9 and 10 roles, women.